Susan Jaffe | Washington Correspondent for The Lancet | 13th January 2016
No single federal agency reviews US drug prices, but 51 members of the U. S. House of Representatives have discovered a 35-year-old law that allows the governme
nt to control huge hikes in drug costs. And they want the Department of Health and Human Services and National Institutes of Health (HHS) to use it. Earlier this week the group led by Texas Democrat Lloyd Doggett wrote to HHS Secretary Sylvia Matthews Burwell and NIH director Dr. Francis Collins to explain why. [Continued here]
The US Congress has become famous for political gridlock but s
offers the best chance we have to save the one planet we have,” Obama said. “We’ve shown that the world has both the will and the ability to take on this challenge.”


period for these private drug and Advantage plans for 2016 starts Thursday and runs through Dec. 7.

t been easy—surviving two Supreme Court challenges, nearly done-in by embarrassing technical glitches, and more than 50 congressional votes attempting to dismantle it. But its troubles are not yet over: enrolling new beneficiaries “is going to be tougher than last year”, warned Health and Human Services (HHS) Secretary Sylvia Mathews Burwell.

